Categories
Change Password!
Reset Password!
In patients with trigeminal neuralgia, a 5% Lidocaine-medicated plaster provides partial symptom relief, making it a viable add-on therapy within multidrug treatment regimens.
In a study published in the “Headache”, a 5% Lidocaine-medicated plaster (LMP) led to partial pain control in certain patients with trigeminal neuralgia. Chunmei Zhao and other authors investigated LMP's safety and efficiency in severe neuropathic facial pain. The PATCH trial was a double-blind, vehicle-controlled, parallel-group study with enriched enrollment and randomized withdrawal, executed at five centers.
Eligible volunteers with trigeminal neuralgia received LMP during an initial 3-week open-label phase. Those fulfilling the response benchmarks were included in the double-blind phase. The enrolled subjects were randomized to get either vehicle patches (control group) or LMP (LMP group). Those with treatment failure were withdrawn, while the remaining subjects continued the intervention for up to 28 days. The study primarily measured therapeutic failures while secondary outcomes estimated the time to therapeutic response loss in the double-blind phase.
Also, mean pain intensity over the week was determined across both double-blind and open-label phases. From an initial pool of 307 screened patients, 226 entered the open-label phase, and 124 proceeded to the double-blind phase. In this phase, 62 patients received LMP, while 62 received the placebo. The results indicated that only 16 patients (26%) in the LMP group experienced therapeutic failure, compared to 36 patients (58%) in the placebo group. For the LMP group, the time to treatment response decline was markedly lengthy (hazard ratio, 0.275).
During the double-blind phase of the study, LMP use was associated with a vital drop in the weekly mean pain severity. To sum up, LMP provides partial pain relief for trigeminal neuralgia sufferers. For those who respond positively, LMP could serve as a valuable addition to a multidrug treatment regimen, offering renewed hope for managing this debilitating condition.
Headache
The PATCH trial: 5% lidocaine-medicated plaster for trigeminal neuralgia-Results of a multicentric, enriched enrollment, randomized withdrawal, double-blind, vehicle-controlled, parallel-group study
Chunmei Zhao et al.
Comments (0)